Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 0 CIVO Study of TAK-186 and Nivolumab in Solid Tumours
NCT04891718Phase 1Withdrawn
- Sponsor
- Presage Biosciences
- Start
- Sep 2021
- Primary completion
- Jun 2022
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAK-186 in solid tumor and head and neck squamous cell carcinoma (HNSCC), sponsored by Presage Biosciences. Primary endpoints: Quantification of Cell Death Biomarkers by IHC and In-Situ Hybridization and Quantification of Immune Cell Biomarkers by IHC and In-Situ Hybridization. Planned start Sep 2021; status: withdrawn.
02
Drugs
TAK-186
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04891718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04891718.